Can a chat increase genetic testing in prostate cancer?
NCT ID NCT05470036
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested whether a brief educational session with a trained educator could increase the number of men with prostate cancer who agree to germline (inherited) genetic testing. The study enrolled 50 men who met national guidelines for testing but had not yet been tested. The goal was to see if education could improve testing rates and patient knowledge.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Educational intervention
- What this could lead to
- If successful, this approach could help more men with prostate cancer get recommended genetic testing, potentially guiding better treatment decisions.
- What could go wrong
- This is a small pilot study with only 50 participants, so results may not apply to all patients. The intervention is educational, not a treatment, so it won't directly affect cancer outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California San Diego
La Jolla, California, 92037, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?